TD Cowen Maintains Buy on AnaptysBio, Lowers Price Target to $70

AnaptysBio, Inc.

AnaptysBio, Inc.

ANAB

0.00

TD Cowen analyst Joseph Thome maintains AnaptysBio (NASDAQ: ANAB) with a Buy and lowers the price target from $75 to $70.